Skip to content

Depression: all studies

Page 741 of 1,034: studies 7,401 to 7,410 of 10,336, newest first. Back to the depression overview

Research

Mindfulness-based online intervention on mental health among undergraduate nursing students during coronavirus disease 2019 pandemic in Beijing, China: A randomized controlled trial.

Frontiers in Psychiatry November 16, 2022 Zhenwei Dai, Shu Jing, Hao Wang et al.

Objective: To evaluate the effect of mindfulness intervention on improving mental health among undergraduate nursing students during the coronavirus disease 2019 (COVID-19) pandemic in China. Methods: An online mindfulness intervention course named Mindfulness Living With Challenge (MLWC) was developed by the research team, and a randomized controlled trial using MLWC among Chinese...

The effects of mindfulness meditation versus CBT for anxiety on emotional distress and attitudes toward seeking mental health treatment: a semi-randomized trial.

Scientific Reports November 16, 2022 Daniela Aisenberg-Shafran, Liav Shturm

Older adults often avoid seeking psychological treatment, thus challenging their ability to cope effectively with anxiety, stress, and depression. The current study aimed to compare the effects of a mindfulness intervention with cognitive behavioral therapy (CBT) on measures of emotional distress and attitudes toward seeking mental health treatment among older adults. Twenty-four seniors were...

The Effect of Meditation, Mindfulness, and Yoga in Patients with Rheumatoid Arthritis.

Journal of Personalized Medicine November 15, 2022 Laura Slagter, Koen Demyttenaere, Patrick Verschueren et al.

Mind-body therapies (MBTs), including meditation, yoga, and mindfulness, create an interaction between the mind and body to enhance health. MBTs are perceived by both patients and healthcare professionals as valuable in the management of rheumatoid arthritis (RA), but the extent of this contribution is unclear, as are the patient subgroups who benefit most from MBTs. Therefore, this systematic...

Manuel de Yale pour la Thérapie de la Dépression Assistée par la Psilocybine

November 15, 2022 Jeffrey Guss, Robert Krause, Jordan Sloshower preprint

This is the French translation of the Yale Manual for Psilocybin-Assisted Therapy of Depression. Le Manuel de Yale pour le traitement thérapeutique de la dépression assisté par la psilocybine fournit aux chercheurs et aux thérapeutes des méthodes, une structure et des domaines à prendre en compte concernant l'utilisation de la thérapie assistée par les psychédéliques dans le traitement du...

Single dose S-ketamine rescues transcriptional dysregulation of Mtor and Nrp2 in the prefrontal cortex of FSL rats 1hour but not 14 days post dosing.

European Neuropsychopharmacology November 11, 2022 Betina Elfving, Nico Liebenberg, Kristian Du Jardin et al.

There is a pressing need to identify biological indicators of major depression to help guide proper diagnosis and optimize treatment. Animal models mimicking aspects of depression constitute essential tools for early-stage exploration of relevant pathways. In this study, we used the Flinders Sensitive and Resistant Line (FSL/FRL) to explore central and peripheral transcriptional changes in...

A Web-Based, Mindful, and Compassionate Parenting Training for Mothers Experiencing Parenting Stress: Results from a Pilot Randomized Controlled Trial of the Mindful Moment Program.

Mindfulness November 10, 2022 Daniela V Fernandes, Fabiana Monteiro, Maria C Canavarro et al.

Objectives: Mindful Moment is a self-guided, web-based, mindful, and compassionate parenting training for postpartum mothers who experience parenting stress. We aimed to assess Mindful Moment's feasibility, acceptability, and usability, and to gather preliminary evidence of its effectiveness in reducing parenting stress and outcomes such as mindful parenting, self-compassion, depressive...

DOI: 10.1007/s12671-022-02016-0 (opens in new tab) Full text (opens in new tab) Postpartum period Parenting stress Web-based intervention Mindful moment

Lusaris launches with $60 million

C&EN Global Enterprise November 7, 2022 Gina Vitale

Lusaris Therapeutics has launched with $60 million in series A financing to develop therapies for severe neuropsychiatric and neurological conditions. The start-up says the type of compounds it is developing, serotonergic neuroplastogens, are able to induce favorable neural plasticity. Its lead candidate, for treatment-resistant depression, is a formulation of the psychedelic 5-Methoxy- N , N...

Effects of mindfulness-based stress reduction on adults with sleep disturbance: an updated systematic review and meta-analysis.

BMJ Open November 4, 2022 Seong Min Kim, Jeong-Min Park, Hyun-Ju Seo et al.

Mindfulness-based stress reduction (MBSR) is a meditation-based therapy originally recommended for stress management. However, it is currently used to alleviate sleep disturbances. Therefore, this contemporary systematic review aimed to elucidate the clinical effects of MBSR on sleep quality and sleep-related daytime impairment in adults with sleep disturbances, including chronic insomnia...

DOI: 10.1136/bmjopen-2021-058032 (opens in new tab) Full text (opens in new tab) Complementary medicine Primary care Sleep medicine

The perceptions of cancer health-care practitioners in New Zealand and the USA toward psychedelic-assisted therapy with cancer patients: A cross-sectional survey

Palliative & Supportive Care November 3, 2022 Lisa Reynolds, Brian S. Barnett, Jeremy Weleff et al. 19 citations

Abstract Objectives A resurgence of research investigating the administration of psychedelic compounds alongside psychotherapy suggests that this treatment is a promising intervention for anxiety, depression, and existential distress in people with cancer. However, psychedelic treatment that induces a mind-altering experience potentially poses barriers to vulnerable cancer patients, and...

Characterization of the Gateway Decarboxylase for Psilocybin Biosynthesis

ChemBioChem November 3, 2022 Tim Schäfer, Kristina Kramer, Sebastiaan Werten et al. 20 citations

Abstract The l ‐tryptophan decarboxylase PsiD catalyzes the initial step of the metabolic cascade to psilocybin, the major indoleethylamine natural product of the “magic” mushrooms and a candidate drug against major depressive disorder. Unlike numerous pyridoxal phosphate (PLP)‐dependent decarboxylases for natural product biosyntheses, PsiD is PLP‐independent and resembles type II...

DOI: 10.1002/cbic.202200551 (opens in new tab) Biochemistry Natural product In silico Serine +1